reports
KDventures´ portfolio company SVF Vaccines appoints Raheleh Nassaji as...
KDventures´ portfolio company SVF Vaccines appoints Raheleh Nassaji as Chief Executive Officer STOCKHOLM, Sweden, 10 February 2026. KDventures AB (Nasdaq Stockholm: KDV) announces that its portfolio company SVF Vaccines has appointed Raheleh Nassaji as Chief Executive Officer to lead the transition of the company’s lead vaccine candidate SVF-001 to phase 1 clinical development. SVF Vaccines develops DNA vaccines and immunotherapies based on proprietary technology originating from Karolinska Institutet. Ahead of entering first-in-human phase 1 clinical development with its lead vaccine cand...
KDventures portföljbolag SVF Vaccines utser Raheleh Nassaji till verks...
KDventures portföljbolag SVF Vaccines utser Raheleh Nassaji till verkställande direktör STOCKHOLM, 10 februari 2026. KDventures AB (Nasdaq Stockholm: KDV) meddelar idag att portföljbolaget SVF Vaccines har utsett Raheleh Nassaji till vd. Hon kommer att leda bolaget i transitionen av bolagets ledande vaccinkandidat SVF-001 till klinisk utveckling i fas 1. SVF Vaccines utvecklar DNA-vaccin och immunterapier baserat på en patenterad teknologi från Karolinska institutet. Inför initieringen av den första kliniska studien med bolagets ledande vaccinkandidat SVF-001, har SVF Vaccines utsett Rahel...
Saia Reports Fourth Quarter Results
Saia Reports Fourth Quarter Results JOHNS CREEK, Ga., Feb. 10, 2026 (GLOBE NEWSWIRE) -- Saia, Inc. (Nasdaq: SAIA), a leading transportation provider offering national less-than-truckload (LTL), non-asset truckload, expedited and logistics services, today reported fourth quarter 2025 financial results. Diluted earnings per share for the quarter were $1.77 compared to $2.84 in the fourth quarter of 2024. Full year diluted earnings per share were $9.52 in 2025 compared to $13.51 in 2024. Excluding a net gain on real estate recorded in the third quarter of 2025, adjusted diluted earnings per ...
Harvard Bioscience Announces Preliminary Fourth Quarter Financial Resu...
Harvard Bioscience Announces Preliminary Fourth Quarter Financial Results, Positive Outlook for 2026 & Outlines Long-Term Strategic Focus Areas Reports preliminary fourth quarter revenue in line with guidance, gross margin at high end of guidance, and strong year over year adjusted EBITDA performance Expects year over year revenue growth and mid-to high-single-digit EBITDA growth in 2026Outlines strategy focused on positioning the company as a leader in the growing translational science tools market while expanding consumables revenue and improving operational performance HOLLISTON, Mass.,...
Streamex Corp. (NASDAQ: STEX) Co-Founder & Executive Chairman Provides...
Streamex Corp. (NASDAQ: STEX) Co-Founder & Executive Chairman Provides Corporate Update WINTER PARK, Fla., Feb. 10, 2026 (GLOBE NEWSWIRE) -- Streamex Corp. (“Streamex” or the “Company”) (NASDAQ: STEX), an institutional-grade digital asset and real-world asset tokenization company, today provided a corporate update from its Co-Founder & Executive Chairman, Morgan Lekstrom, highlighting recent strategic progress, balance sheet strength, insider alignment, preparations for the upcoming launch of GLDY, and the 2026 strategic roadmap. Executive Chairman Commentary Morgan Lekstrom, Co-Founder...
Wrap Technologies Conducts Instructor Retraining and Program Expansion...
Wrap Technologies Conducts Instructor Retraining and Program Expansion with Malta National Police Force Training reinforced Non-Lethal Response (NLR) solution combined with BolaWrap’s deployment philosophy supports academy integration and positions agency for nationwide rollout MIAMI, Feb. 10, 2026 (GLOBE NEWSWIRE) -- Wrap Technologies, Inc. (NASDAQ: WRAP) (“Wrap” or, the “Company”), a global leader in non-lethal response and public safety technology, today announced the successful completion of instructor retraining and new instructor certification with the Malta National Police Force,...
Helus Pharma Appoints Michael Cola as Chief Executive Officer to Lead ...
Helus Pharma Appoints Michael Cola as Chief Executive Officer to Lead Next Phase of Scale and Execution Former President of Shire PLC’s (“Shire”) Specialty Pharmaceutical business, with more than 30 years of experience across neuroscience, rare disease, and specialty pharmaceuticals, including senior leadership roles at Astra-Merck and AstraZeneca PLCProven leader in late-stage clinical development, global commercialization, and capital formation across central nervous system (“CNS”) programsAppointed as Helus Pharma advances its pipeline toward key clinical milestones, including expected P...
Medicus Pharma Receives FDA “Study May Proceed” Clearance For Tevereli...
Medicus Pharma Receives FDA “Study May Proceed” Clearance For Teverelix® Phase 2b Study in Advanced Prostate Cancer Patients with High Cardiovascular Risk The Company is developing Teverelix® as a best-in-class market product for advanced prostate cancer patients with high CV risk and a first in class product for Acute Urinary Retention Relapse prevention (AURr) collectively representing ~US$6 billion in potential market opportunity PHILADELPHIA, Feb. 10, 2026 (GLOBE NEWSWIRE) -- Medicus Pharma Ltd. (NASDAQ: MDCX) ("Medicus" or the "Company"), a precision guided biotech/life sciences co...
Repligen to Report Fourth Quarter and Full Year 2025 Financial Results
Repligen to Report Fourth Quarter and Full Year 2025 Financial Results Webcast and Conference Call to Be Held Tuesday, February 24, 2026, at 8:30 a.m. ET WALTHAM, Mass., Feb. 10, 2026 (GLOBE NEWSWIRE) -- Repligen Corporation (NASDAQ:RGEN) today announced that the Company will report its fourth quarter 2025 financial results on Tuesday, February 24, 2026. The Company will issue a press release before the market opens and will host a conference call at 8:30 a.m. ET to discuss business updates and financial results for the three- and twelve- month reporting periods ended December 31, 2025....
Insurance Shopping Bucked Traditional Year-End Slump, Remaining Elevat...
Insurance Shopping Bucked Traditional Year-End Slump, Remaining Elevated in Q4 2025 TransUnion’s latest quarterly report finds regular insurance shopping the new normal CHICAGO, Feb. 10, 2026 (GLOBE NEWSWIRE) -- Insurance shopping is now a routine activity for consumers rather than a rare event prompted by a car or home purchase. TransUnion (NYSE: TRU) analysts drew this conclusion after tracking three years of steadily increasing insurance shopping rates in the quarterly . Most recently, 2025 fourth quarter data showed that elevated shopping levels continued throughout a season in whi...
Gilat Reports Fourth Quarter and Full Year 2025 Results
Gilat Reports Fourth Quarter and Full Year 2025 Results Q4 Revenue of $137.0 million, GAAP Operating Income of $13.0 million and Adjusted EBITDA of $18.2 million 2025 Revenue of $451.7 million, GAAP Operating Income of $23.4 million and a Record Adjusted EBITDA of $53.2 million Guidance1 for 2026 Calls for Double Digit Revenue and Adjusted EBITDA Growth PETAH TIKVA, Israel, Feb. 10, 2026 (GLOBE NEWSWIRE) -- Gilat Satellite Networks Ltd. (NASDAQ: GILT, TASE: GILT), a worldwide leader in satellite networking technology, solutions and services, today reported its results for the fourth qu...
Leadership Changes
Leadership Changes THIS ANNOUNCEMENT CONTAINS INSIDE INFORMATION FOR THE PURPOSES OF ARTICLE 7 OF THE MARKET ABUSE REGULATION (EU) 596/2014 AS IT FORMS PART OF UK DOMESTIC LAW BY VIRTUE OF THE EUROPEAN UNION (WITHDRAWAL) ACT 2018. Cambridge, UK, 10 February 2026 – 4basebio PLC (AIM: 4BB), an innovation driven biotechnology company enabling and accelerating development of advanced therapy medicinal products (ATMPs) through its high performant GMP-grade synthetic DNA products, announces that Dr Amy Walker has been appointed as Chief Executive Officer, succeeding Dr Heikki Lanckriet, Founder ...
Axogen, Inc. to Report Fourth Quarter and Full Year 2025 Financial Res...
Axogen, Inc. to Report Fourth Quarter and Full Year 2025 Financial Results on February 24, 2026 ALACHUA, Fla. and TAMPA, Fla., Feb. 10, 2026 (GLOBE NEWSWIRE) -- Axogen, Inc. (Nasdaq: AXGN), a global leader in developing and marketing innovative surgical solutions for the restoration of peripheral nerve function, today announced that it will release financial results for the fourth quarter and full year 2025 on Tuesday, February 24, 2026. Axogen management will host an investment-community conference call and webcast at 8:00 a.m. ET following the release. Investors interested in participa...
Standard BioTools to Announce Fourth Quarter and Full Year 2025 Financ...
Standard BioTools to Announce Fourth Quarter and Full Year 2025 Financial Results on February 24, 2026 BOSTON, Mass., Feb. 10, 2026 (GLOBE NEWSWIRE) -- Standard BioTools Inc. (NASDAQ: LAB) today announced that it will publish fourth quarter and full year 2025 financial results on Tuesday, February 24, 2026, after U.S. market close. About Standard BioTools Inc. Standard BioTools Inc. (Nasdaq: LAB), has an established portfolio of essential, standardized next-generation technologies that help biomedical researchers develop better medicines faster. As a leading solutions provider, the comp...
Bread Financial Provides Performance Update for January 2026
Bread Financial Provides Performance Update for January 2026 COLUMBUS, Ohio, Feb. 10, 2026 (GLOBE NEWSWIRE) -- (NYSE: BFH), a tech-forward financial services company that provides simple, personalized payment, lending, and saving solutions to millions of U.S. consumers, provided a performance update. The following tables present the Company’s Net principal loss rate and Delinquency rate for the periods indicated: For themonth endedJanuary 31, 2026 For themonth endedJanuary 31, 2025 (dollars in millions)End-of-period credit card and other loans$18,386 $18,366 Average credit card and oth...
New Flyer receives order for 100 additional transit buses for the Wash...
New Flyer receives order for 100 additional transit buses for the Washington Metro Region Washington Metro continues to modernize its fleet with New Flyer hybrid and battery-electric buses ST. CLOUD, Minn., Feb. 10, 2026 (GLOBE NEWSWIRE) -- (TSX: NFI, OTC: NFYEF, TSX: NFI.DB) New Flyer of America Inc. (New Flyer), a leader in the transit industry and a subsidiary of NFI Group Inc. (NFI), today announced that Washington Metropolitan Area Transit Authority (“Metro”) has exercised options for 75 Xcelsior® hybrid-electric forty-foot transit buses and 25 Xcelsior CHARGE NG™ battery-electr...
Manhattan Bridge Capital, Inc. Declares Quarterly Dividend
Manhattan Bridge Capital, Inc. Declares Quarterly Dividend GREAT NECK, N.Y., Feb. 10, 2026 (GLOBE NEWSWIRE) -- Manhattan Bridge Capital, Inc. (NASDAQ: ) announced today that its board of directors has declared a quarterly dividend of $0.11 per share to be paid to all shareholders of record on April 8, 2026. The dividend will be paid on April 15, 2026. Contact: Assaf Ran, CEO (516) 444-3400 SOURCE: Manhattan Bridge Capital, Inc.
Aeluma Names Bouchaib Nessar Senior Vice President of Business Develop...
Aeluma Names Bouchaib Nessar Senior Vice President of Business Development and Product Key Appointment to Drive Commercialization Strategy as Markets Ramp and Company Generates Initial Sales GOLETA, Calif., Feb. 10, 2026 (GLOBE NEWSWIRE) -- Aeluma, Inc. (NASDAQ: ALMU), a semiconductor company specializing in high-performance, scalable technologies for mobile, AI, defense and aerospace, robotics, automotive, AR/VR, and quantum, announced today it has named Bouchaib Nessar as its Senior Vice President of Business Development and Product to lead its go-to-market strategy across communicati...
Aurora Mobile’s GPTBots.ai and Hong Kong Ants Asia Forge Strategic Par...
Aurora Mobile’s GPTBots.ai and Hong Kong Ants Asia Forge Strategic Partnership for AI Innovation HONG KONG, Feb. 10, 2026 (GLOBE NEWSWIRE) -- Aurora Mobile Limited (NASDAQ: JG) (“Aurora Mobile” or the “Company”), a leading provider of customer engagement and marketing technology services in China, today announced that its enterprise-grade AI agent platform, , has established a strategic partnership with Ants Asia Limited, a leading enterprise AI solutions specialist deeply rooted in the Hong Kong market. This collaboration combines GPTBots.ai’s powerful no-code infrastructure with Ants As...
Sutro Biopharma Announces Pricing of $110.0 million Underwritten Offer...
Sutro Biopharma Announces Pricing of $110.0 million Underwritten Offering SOUTH SAN FRANCISCO, Calif., Feb. 10, 2026 (GLOBE NEWSWIRE) -- Sutro Biopharma, Inc. (Sutro or the Company) (Nasdaq: STRO), a clinical-stage oncology company pioneering site-specific and novel-format antibody drug conjugates (ADCs), today announced the pricing of an underwritten offering of 7,868,383 shares of its common stock at a price of $13.98 per share. The gross proceeds from this offering are expected to be approximately $110.0 million, before deducting underwriting discounts and commissions and other offerin...
Unfortunately, this report is not available for the investor type or country you selected.
Report is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.